Cardiac involvement, including progressive cardiomyopathy, is common in Fabry disease and is a leading cause of premature mortality. We sought to determine if tissue Doppler imaging (TDI) could identify Fabry disease patients at risk for the development of cardiomyopathy and if enzyme replacement therapy (ERT) with agalsidase alfa might slow or prevent the progression of cardiac involvement.
Introduction
Fabry disease (OMIM 301500) is a rare, inherited, X-linked deficiency in the activity of the lysosomal enzyme a-galactosidase A (a-Gal A). 1, 2 In affected individuals, cellular accumulation of the principal enzyme substrate, globotriaosylceramide (Gb3), occurs and contributes to the signs and symptoms of the disease. In males, the onset of signs and symptoms of Fabry disease occurs in childhood and adolescence and is characterized by acroparesthesias and neuropathic pain, gastrointestinal problems including pain and diarrhea, hypohydrosis and heat intolerance, angiokeratoma, and characteristic corneal opacities. 3 -5 As the disease progresses, kidney dysfunction, cardiac involvement, and stroke increase in prevalence and contribute to premature mortality in men. 6 Although women have been considered to be mere carriers of the mutation, it has recently become evident that they could experience nearly all the signs and symptoms of Fabry disease, but with a later onset and a more variable expression than seen in men. 7, 8 Cardiac involvement is common in patients with Fabry disease and includes left ventricular hypertrophy (LVH), valvular dysfunction, and conduction abnormalities. 9 -11 Left ventricular (LV) wall thickening is the most common cardiac sign of Fabry disease, with increases in mass sometimes so large as to mimic hypertrophic cardiomyopathy. 9, 12 As the disease progresses, interstitial fibrosis is commonly observed, 12 -14 resulting in systolic and diastolic dysfunction. Tissue Doppler imaging (TDI) is emerging as an accepted method for identifying the early stages of several forms of inherited cardiomyopathy. 15, 16 TDI has been reported to distinguish between patients with Fabry disease with and without LVH and relatives without the Fabry disease mutation. 17 We have recently reported that TDI measurements can distinguish between Fabry disease patients with and without LVH, as well as between Fabry disease patients without LVH and healthy subjects without the disease. 18 However, to date, no prognostic information of TDI measurements has been reported in patients with Fabry disease. Thus, this longitudinal study was performed to investigate the prognostic information provided by tissue Doppler echocardiography in patients with Fabry disease and to evaluate the effect of enzyme replacement therapy (ERT) on the progression of Fabry disease cardiomyopathy.
Methods
This study was a prospective, blinded, observational study of male and female patients with a confirmed diagnosis of Fabry disease. In the male patients, diagnosis was made by a biochemical demonstration of a reduction in the activity of a-Gal A in peripheral leukocytes. DNA analysis was used to confirm Fabry disease in female patients. Patients were recruited into the study without regard for current or past use of ERT. All patients gave their informed written consent prior to enrolling in the study, and the study protocol was reviewed and approved by the ethics committee of the San Carlos University Hospital in Madrid, Spain. All patients were evaluated at least two times during this study, first at study entry (baseline) and thereafter at 6-to 12-months intervals. At each study evaluation, the following assessments were made: medical history, physical examination, supine 12-lead electrocardiogram, and echocardiography. 
Results
A total of 76 patients (26 men and 50 women) with Fabry disease were enrolled in the study. Twenty of the men and 13 of the women were being treated with agalsidase alfa (Replagal w , Shire Human Genetic Therapies, Cambridge, MA, USA) at a dose of 0.2 mg/kg infused intravenously every other week. The infusion period was 40 min, and premedication was not reported at the time of enrollment nor throughout the study. Follow-up data were available for 63 patients, and of these, 55 patients were .18 years old: 36 female (12 treated) and 19 males (16 treated). Agalsidase alfa is human cell line-derived a-gal A that is indicated for long-term ERT in Fabry disease. 20 Baseline echocardiographic data from some of these patients have been previously described. 18 
Echocardiography
Baseline 2D echocardiography measurements are presented in Table 1 . As expected, the prevalence of LVH was higher in ERTtreated men and women than in the untreated men and women. This data are in accordance with the scientific evidence, as Values are mean + standard deviation (range). IVSd, interventricular septum thickness measured during diastole; PWTd, posterior wall thickness measured during diastole. *P , 0.05 compared with untreated women (t-test).
according to current Fabry guidelines LVH is a clear marker to start ERT treatment, and very few patients actually start ERT before LVH is present, what sometimes could be too late for a beneficial effect. Ejection fraction was normal in both treated and untreated men and women. Over the course of up to 4.9 years of follow-up examinations, no significant changes in average 2D echocardiographic measurements were found. For example, untreated women demonstrated an average change from baseline of interventricular septum thickness measured during diastole (IVSd) of 0.29 + 1.73 mm (mean + SD) after a median of 2.9 years of follow-up. Baseline TDI assessments are presented in Table 2 . ERT-treated women had significantly lower Ea-lateral and Sa-lateral velocities compared with their untreated counterparts. A higher percentage of ERT-treated men (75.0%) and women (53.8%) were designated as having an abnormal TDI velocity than untreated men (16.7%) and women (16.2%).
The association between Ea-septal TDI velocity and interventricular septum thickness at baseline in the entire study population is presented in Figure 1 . Ea-septal TDI velocity was inversely associated with interventricular septum thickness over the entire range of baseline values (P , 0.0001, regression analysis).
The abnormal TDI identified patients who were at risk for developing LVH during the longitudinal follow-up. TDI images from a patient with normal TDI velocities at baseline who progressed to abnormal TDI velocities are shown in Figure 2 . At baseline, 23 women .18 years old had both normal TDI velocities and normal LVM, 7 women had abnormal TDI velocities and normal LVM, and 6 had both abnormal TDI velocities and an increased LVM. After a median 2.9 years of follow-up, this distribution had changed to 8 normal, 18 with abnormal TDI, and 10 with both abnormal TDI and LVH. A similar shift was seen in men. At baseline, 6 men had normal TDI velocities and normal LVM, 5 had abnormal TDI velocities and normal LVM, and 8 had both abnormal TDI velocities and LVH. After a median 3.4-year follow-up, the distribution had shifted to 3, 5, and 11 men, respectively.
The influence of ERT with agalsidase alfa on the progression of cardiac involvement in Fabry disease was very important. In the cohort of patients who had no evidence of cardiac involvement at baseline, 80% (16 of 20 patients) of patients not on ERT progressed to demonstrating an abnormal TDI velocity during follow-up, whereas only 33% (3 of 9) of patients on ERT progressed to TDI abnormalities (P ¼ 0.031; Tables 3 and 4).
Assessment of diastolic dysfunction has also been studied. Of interest E/e' ratio was lower in the lateral annulus, which may be due to the interaction of the right ventricle at the mid-annulus ( Table 5 ) and diastolic dysfunction was more present in those patients receiving ERT ( Table 6 ). This may be related to the more frequency of LVH among the treated patients.
Discussion
In this study, echocardiography was performed on both male and female patients with Fabry disease. Our results showed that TDI velocities were inversely related to LVM (Figure 1 ). In addition, the serial follow-up echocardiographic examinations clearly demonstrated that abnormal TDI velocities were evident prior to the development of LVH. Moreover, ERT was significantly associated with preventing the development of abnormal TDI velocities in patients without evidence of cardiac involvement at baseline.
The TDI velocities of patients with Fabry disease in this study are of the magnitude previously reported in Fabry patients with or without LVH. 17 Previous studies have identified reduced TDI velocities in Fabry patients without echocardiographic evidence of Fabry-related cardiomyopathy. 17, 18, 22 The observation that TDI velocities are further reduced in Fabry patients with LVH has suggested that TDI abnormalities might be an initial finding of cardiac involvement in Fabry disease. The present study is the first to use TDI to longitudinally follow individual Fabry disease patients, and has documented that indeed, reduced TDI velocities appear to precede the development of LVH in all cases. Cardiac involvement is common in both men and women with Fabry disease. Gb3 accumulates within all components of the heart (e.g. cardiomyocytes, conduction system, valvular cells, vascular endothelial cells, smooth muscle cells). 10 It is thought that this accumulation of Gb3, which represents only 1 -2% of the total cardiac mass, stimulates the activation of other signalling pathways that lead to the hypertrophy and fibrosis. 10 Fabry-related cardiomyopathy is characterized by concentric remodelling usually progressing to a concentric hypertrophy. 9, 24 A recent report from the Fabry Outcome Survey found that the prevalence of LVH diagnosed by echocardiography increased with age in both men and women. 11 About 25% of all men were diagnosed with LVH by about age 42 years; the diagnosis of LVH in women occurred about 10 years later. 11 Although the onset of clinical heart disease in men with Fabry disease usually occurs in the third decade of life, cardiac involvement has been reported in boys as young as 6 years old. 4 Similarly, cardiac disease has been reported in female Fabry patients as young as 15 years old. 3 Cardiac involvement is a common cause of death in both male and female Fabry disease patients.
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Management of Fabry disease has historically been directed at symptoms; however, the development of human a-Gal A for ERT has opened the possibility of treating this genetic disease. 20, 25 Two forms of human a-Gal A have been developed: agalsidase alfa, which is produced in a continuous human cell line and agalsidase beta (Fabrazyme w , Genzyme, Cambridge, MA, USA), which is produced in Chinese hamster ovary cells. These two forms of the enzyme have identical amino acid sequences, but have different glycosylation patterns due to the different cell cultures used in their manufacture, and this difference may reflect the difference in safety profile and different dosage seen for each drug. 26 Both forms of the enzyme have been reported to slow the progression of kidney dysfunction. 27, 28 Agalsidase alfa has been reported to reduce the severity of neuropathic pain. 20 In studies directly related to the present results, agalsidase alfa has been reported to reduce LVM in adult male 29 and adult female 30, 31 Fabry disease patients with baseline LVH and to improve heart rate variability in adolescent male patients. 32 Agalsidase beta also has been tested for its ability to influence Fabry-related cardiomyopathy, with some studies finding a reduction in LVM 33, 34 and others reporting no or mixed response. 34 -38 The variation in response to ERT seen in some patients has led investigators to suggest that ERT may be less effective in slowing or stopping the progression of Fabry disease when used in patients in an advanced stage of the disease. 27, 29, 39, 40 However as seen in our cohort, that included patients with different burden of the disease, prevalence of LVH was higher in ERT-treated men and women than in the untreated men and women, suggesting that treatment is still started only when there is organ damage, that could be late in some patients for seeing a beneficial effect of ERT, being early diagnosis a crucial point. The influence of age is still a controversial issue. On the one hand it could of course contribute to the abnormal findings as patients treated are normally older and more affected than untreated patients due to the progressive course of the disease. However, it is also important to mention that as there is no clear correlation between genetic mutations and burden of the disease, patients affected may sometimes be younger than unaffected ones.
The observations in the present study confirm that to slow or prevent the progression of organ damage, it is important to identify patients at an early stage of the disease, and to initiate ERT at an early stage, because some of the pathological changes are potentially irreversible (e.g. myocardial fibrosis). 39, 40 Current guidelines indicate that all males over the age of 16 years should be offered ERT, 41 a strategy that should ensure the initiation of ERT before major organ damage has progressed to irreversible stages in most patients. However, for women with Fabry disease, the same guidelines state that ERT should only be initiated if significant symptoms develop or if evidence of progression of organ involvement is detected. In the case of the heart, delaying ERT until clinically significant cardiac involvement is present may be too late to positively influence its progression. The results of the present study indicate that signs of cardiomyopathy can be detected by TDI before it is clinically evident, and suggest that ERT may slow the progression of cardiac involvement before irreversible changes occur if started early enough. Of the Fabry patients without evidence of cardiac involvement (i.e. normal TDI) at baseline, 80% of the untreated patients progressed to demonstrating abnormal TDI velocities during follow-up, whereas only 33% of patients treated with ERT showed similar progression. This is an important observation because it supports early initiation of ERT, even before TDI abnormalities can be detected. To clearly understand the potential benefits of early ERT on the heart it is of utmost importance to recognize that nearly all Fabry patients progress to LVH 40 and cardiac involvement contributes substantially to disease-related morbidity and mortality in men and is the major cause of premature death in heterozygous females.
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Study limitations
Although the investigators performing and evaluating the echocardiographic examinations were blinded to the ERT status of the study participants, the study was otherwise open and observational in nature. Study subjects were not randomly selected for ERT, and they were at a more advanced stage of cardiac involvement compared with the untreated patients. Because some patients were treated with agalsidase alfa upon entry to the study, no pretreatment measurements were available for these patients. Thus, the initial response of TDI velocities or 2D echocardiographic measurements to agalsidase alfa could not be evaluated. Future controlled clinical studies will be required to confirm whether early initiation of ERT in women or men before TDI velocities have declined can slow or stop the progression of Fabry-related cardiomyopathy.
Conclusions
In Fabry patients, disease progression and the degree of organ involvement at the time ERT is initiated are crucial for prognosis and response to therapy. In Fabry disease, the appearance of reduced TDI velocities may be the initial sign of cardiac involvement and occurs before LVH can be detected. Early institution of ERT with agalsidase alfa appeared to slow the progression of cardiac involvement in Fabry disease. Our data suggest that ERT should be considered at an early stage of the disease to avoid further progression of the cardiac disease.
